InMed Pharmaceuticals Plans to Sell 3.9 Million Common Shares for Existing Holders

InMed Pharmaceuticals has filed to sell 3.9 million common shares for holders.

InMed Pharmaceuticals (NASDAQ: INM) has filed a prospectus to resell up to 3.9 million common shares, as reported on July 9, 2025. The offering includes 1.95 million shares from pre-funded warrants and 1.95 million shares from preferred investment options, both issued under a private placement. The company will not receive proceeds from the resale of shares but may receive up to $4.76 million from the exercise of preferred investment options, and $195 from pre-funded warrants if exercised for cash [1].

The shares will be sold by a selling shareholder and its permitted transferees. InMed Pharmaceuticals is listed on the Nasdaq Capital Market under the symbol "INM" and has a last reported sale price of $2.73 per share as of July 7, 2025. The company is classified as an "emerging growth company" and a "smaller reporting company," which means it is subject to reduced public company reporting requirements [2].

Investors are advised to carefully review the prospectus, including the section on "Risk Factors," before making any investment decisions. The prospectus is subject to completion and may be amended from time to time.

References:
[1] https://seekingalpha.com/news/4466308-inmed-pharmaceuticals-registers-39m-shares-for-resale
[2] https://www.stocktitan.net/sec-filings/INM/s-1-in-med-pharmaceuticals-inc-files-ipo-registration-statement-0af9f6471773.html